ALGBE Fundamental Analysis - GLOBAL BIOENERGIES SA

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALGBE. ALGBE was compared to 69 industry peers in the Chemicals industry. Both the profitability and financial health of ALGBE have multiple concerns. ALGBE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGBE has reported negative net income.

ALGBE had a negative operating cash flow in the past year.

ALGBE had negative earnings in each of the past 5 years.

ALGBE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ALGBE's Return On Assets of -60.73% is on the low side compared to the rest of the industry. ALGBE is outperformed by 94.20% of its industry peers.

Looking at the Return On Equity, with a value of -346.31%, ALGBE is doing worse than 92.75% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROIC	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGBE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGBE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALGBE remains at a similar level compared to 1 year ago.

ALGBE has more shares outstanding than it did 5 years ago.

ALGBE has a worse debt/assets ratio than last year.

2.2 Solvency

ALGBE has an Altman-Z score of -2.42. This is a bad value and indicates that ALGBE is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.42, ALGBE is doing worse than 89.86% of the companies in the same industry.

A Debt/Equity ratio of 2.78 is on the high side and indicates that ALGBE has dependencies on debt financing.

ALGBE has a Debt to Equity ratio of 2.78. This is amonst the worse of the industry: ALGBE underperforms 91.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Altman-Z	-2.42

ROIC/WACCN/A

WACC6.66%

2.3 Liquidity

ALGBE has a Current Ratio of 2.86. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ALGBE (2.86) is better than 84.06% of its industry peers.

A Quick Ratio of 2.73 indicates that ALGBE has no problem at all paying its short term obligations.

ALGBE has a Quick ratio of 2.73. This is amongst the best in the industry. ALGBE outperforms 92.75% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.86
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.31% over the past year.

ALGBE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -88.90%.

The Revenue has been growing by 25.15% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

3.2 Future

Based on estimates for the next years, ALGBE will show a decrease in Earnings Per Share. The EPS will decrease by -5.13% on average per year.

Based on estimates for the next years, ALGBE will show a small growth in Revenue. The Revenue will grow by 0.48% on average per year.

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALGBE. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGBE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALGBE's earnings are expected to decrease with -5.13% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGBE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLOBAL BIOENERGIES SA

EPA:ALGBE (6/18/2025, 7:00:00 PM)

0.0905

-0.02 (-18.47%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)N/A N/A

Earnings (Next)09-08 2025-09-08

Inst Owners1.07%

Inst Owner ChangeN/A

Ins Owners2.68%

Ins Owner ChangeN/A

Market Cap1.64M

Analysts84.44

Price Target3.37 (3623.76%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)2.22%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.56
P/FCF	N/A
P/OCF	N/A
P/B	0.97
P/tB	1.01
EV/EBITDA	N/A

EPS(TTM)-0.32

EYN/A

EPS(NY)-0.23

Fwd EYN/A

FCF(TTM)-0.44

FCFYN/A

OCF(TTM)-0.41

OCFYN/A

SpS0.02

BVpS0.09

TBVpS0.09

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score0

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.66%
Cap/Sales	129.34%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.86
Quick Ratio	2.73
Altman-Z	-2.42

F-Score0

WACC6.66%

ROIC/WACCN/A

Cap/Depr(3y)101.02%

Cap/Depr(5y)112%

Cap/Sales(3y)139.76%

Cap/Sales(5y)838.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year29.13%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y3.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.94%

OCF growth 3YN/A

OCF growth 5YN/A

GLOBAL BIOENERGIES SA (ALGBE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens